396 related articles for article (PubMed ID: 33635546)
21. Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.
Wang W; Zhao X; Wei W; Fan W; Gao K; He S; Zhuang X
BMC Infect Dis; 2021 Jan; 21(1):114. PubMed ID: 33494713
[TBL] [Abstract][Full Text] [Related]
22. The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.
Casucci G; Acanfora D; Incalzi RA
Drugs Aging; 2020 Nov; 37(11):779-785. PubMed ID: 33084001
[TBL] [Abstract][Full Text] [Related]
23. Effect of Renin-Angiotensin-Aldosterone System Inhibitors on Short-Term Mortality After Sepsis: A Population-Based Cohort Study.
Hsu WT; Galm BP; Schrank G; Hsu TC; Lee SH; Park JY; Lee CC
Hypertension; 2020 Feb; 75(2):483-491. PubMed ID: 31838905
[TBL] [Abstract][Full Text] [Related]
24. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
[TBL] [Abstract][Full Text] [Related]
25. Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review.
Ferrari F; Martins VM; Fuchs FD; Stein R
Clinics (Sao Paulo); 2021; 76():e2342. PubMed ID: 33852652
[TBL] [Abstract][Full Text] [Related]
26. Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?
Bavishi C; Bangalore S; Messerli FH
Prog Cardiovasc Dis; 2016; 59(3):253-261. PubMed ID: 27777044
[TBL] [Abstract][Full Text] [Related]
27. Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction.
Vaduganathan M; Fonarow GC; Greene SJ; Devore AD; Albert NM; Duffy CI; Hill CL; Patterson JH; Spertus JA; Thomas LE; Williams FB; Hernandez AF; Butler J
J Card Fail; 2022 Feb; 28(2):191-201. PubMed ID: 34428591
[TBL] [Abstract][Full Text] [Related]
28. Impact of renin-angiotensin-aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study.
Sato K; White N; Fanning JP; Obonyo N; Yamashita MH; Appadurai V; Ciullo A; May M; Worku ET; Helms L; Ohshimo S; Juzar DA; Suen JY; Bassi GL; Fraser JF; Arora RC;
BMC Cardiovasc Disord; 2022 Mar; 22(1):123. PubMed ID: 35321649
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019.
Suh SH; Ma SK; Kim SW; Bae EH
Korean J Intern Med; 2021 Mar; 36(2):247-262. PubMed ID: 33617712
[TBL] [Abstract][Full Text] [Related]
30. Renin-Angiotensin-Aldosterone System Inhibitors and Risks of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Systematic Review and Meta-Analysis.
Chan CK; Huang YS; Liao HW; Tsai IJ; Sun CY; Pan HC; Chueh JS; Wang JT; Wu VC; Chu TS;
Hypertension; 2020 Nov; 76(5):1563-1571. PubMed ID: 32869673
[TBL] [Abstract][Full Text] [Related]
31. Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis.
Savarese G; Benson L; Sundström J; Lund LH
Eur J Heart Fail; 2021 Mar; 23(3):476-485. PubMed ID: 33222412
[TBL] [Abstract][Full Text] [Related]
32. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea.
Son M; Seo J; Yang S
Hypertension; 2020 Sep; 76(3):742-749. PubMed ID: 32654557
[TBL] [Abstract][Full Text] [Related]
33. Relation Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Severity.
Alhaddad MJ; Almulaify MS; Alshabib AA; Alwesaibi AA; Alkhameys MA; Alsenan ZK; Alsheef HJ; Alsaghirat MA; Almomtan MS; Alshakhs MN
Cureus; 2022 Mar; 14(3):e22903. PubMed ID: 35399441
[TBL] [Abstract][Full Text] [Related]
34. Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension.
Chen R; Yang J; Gao X; Ding X; Yang Y; Shen Y; He C; Xiang H; Ke J; Yuan F; Cheng R; Lv H; Li P; Zhang L; Liu C; Tan H; Huang L
J Clin Hypertens (Greenwich); 2020 Nov; 22(11):1974-1983. PubMed ID: 33006442
[TBL] [Abstract][Full Text] [Related]
35. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.
Ferrario CM
Life Sci; 2010 Feb; 86(9-10):289-99. PubMed ID: 19958778
[TBL] [Abstract][Full Text] [Related]
36. Effects of RAAS Inhibitors in Patients with Kidney Disease.
Zhang F; Liu H; Liu D; Liu Y; Li H; Tan X; Liu F; Peng Y; Zhang H
Curr Hypertens Rep; 2017 Aug; 19(9):72. PubMed ID: 28791529
[TBL] [Abstract][Full Text] [Related]
37. Should ACE inhibitors and ARBs be used in combination in children?
Stotter BR; Ferguson MA
Pediatr Nephrol; 2019 Sep; 34(9):1521-1532. PubMed ID: 30112656
[TBL] [Abstract][Full Text] [Related]
38. Chronic use of renin-angiotensin-aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis.
Aparisi Á; Catalá P; Amat-Santos IJ; Marcos-Mangas M; López-Otero D; Veras C; López-Pais J; Cabezón-Villalba G; Cacho Antonio CE; Candela J; Antúnez-Muiños P; Gil JF; González Ferrero T; Rojas G; Pérez-Poza M; Uribarri A; Otero-García O; García-Granja PE; Jiménez Ramos V; Revilla A; Dueñas C; Gómez I; González-Juanatey JR; San Román JA
Med Clin (Barc); 2022 Apr; 158(7):315-323. PubMed ID: 34088524
[TBL] [Abstract][Full Text] [Related]
39. RAAS inhibitors are associated with a better chance of surviving of inpatients with Covid-19 without a diagnosis of diabetes mellitus, compared with similar patients who did not require antihypertensive therapy or were treated with other antihypertensives.
Khalangot M; Sheichenko N; Gurianov V; Zakharchenko T; Kravchenko V; Tronko M
Front Endocrinol (Lausanne); 2023; 14():1077959. PubMed ID: 36755914
[TBL] [Abstract][Full Text] [Related]
40. Risk of SARS-CoV-2 infection and COVID-19 prognosis with the use of renin-angiotensin-aldosterone system (RAAS) inhibitors: a systematic review.
Iheanacho CO; Odili VU; Eze UIH
Futur J Pharm Sci; 2021; 7(1):73. PubMed ID: 33778087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
